Switching from Desvenlafaxine to Duloxetine

Introduction to Switching Protocol

• The Mayo Clinic recommends a cross-taper approach when switching from desvenlafaxine to duloxetine to maintain therapeutic coverage and minimize withdrawal symptoms 1, 2

Cross-Tapering Protocol

• Start duloxetine at 30 mg once daily while reducing desvenlafaxine by half for one week, then discontinue desvenlafaxine and increase duloxetine to 60 mg daily 1
• For elderly or frail patients, consider starting duloxetine at 20 mg with a slower cross-taper schedule over 10-14 days to limit withdrawal symptoms 1

Special Considerations

• Duloxetine dosage requires adjustment in patients with renal impairment and should be avoided in severe renal impairment 1, 3
• The American Academy of Child and Adolescent Psychiatry notes that both SNRIs can increase blood pressure and pulse, but duloxetine may have more pronounced effects 2

Monitoring Requirements

• Monitor blood pressure and pulse regularly during the transition, as both SNRIs can increase these parameters 1, 2
• Nausea is the most common side effect when starting duloxetine, with other common effects including dry mouth, headache, constipation, dizziness, and fatigue 1, 3

Critical Safety Considerations

• Avoid combining duloxetine with MAOIs due to the risk of serotonin syndrome 2
• Exercise caution with CYP1A2 and CYP2D6 substrates, as duloxetine interacts with these pathways 2, 3
• Monitor for rare but serious adverse effects, including hepatic failure, severe skin reactions, suicidal thinking and behavior, and serotonin syndrome 2, 3

Target Dosing and Titration

• The standard therapeutic dose of duloxetine is 60 mg once daily, with a maximum dose of 120 mg daily if clinically indicated 1, 3